Cevira

Cevira is in development as a local treatment for Cervical intraepithelial neoplasia lesions and human papilloma virus (HPV) of the cervix without damaging healthy tissue. With Cevira, Photocure aims to develop the first non-surgical treatment for precancerous cervical lesions using photodynamic therapy (PDT). Cevira treatment is administered locally and remains in contact with the cervix to deliver treatment for up to 24 hours. A cup holds the ointment against the cervix for initial absorption. After a few hours, a light source within the cup emits light at a specific wavelength so the Active Pharmaceutical Ingredient, hexylaminolevulinate (HAL), react with the tissue.[1][2]

References

  1. ↑ "Photodynamic Device Developed to Treat Precancerous Cervical Lesions". Medical Advice Network. 18 March 2011. Retrieved 2013-06-06.
  2. ↑ Fontanazza, Maria (April 18, 2011). "Drug and Light Join Forces to Fight Precancerous Lesions". MDDI. Archived from the original on April 14, 2013. Retrieved 2013-06-06.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.